quality of care

Research in Review

06/15/2017

JCP Editors

A recent study demonstrated high response rates and tolerable safety profiles in pediatric patients with chronic myeloid leukemia (CML) after treatment with a tyrosine kinase inhibitor (TKI). ----- Related...

A...

06/15/2017

Journal of Clinical Pathways

Feature

Malnutrition Management: A Clinical Pathway Model for Symptom Management

06/14/2017

Emily Chan , MD;

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Nader Tavakoli , MD, CMD, FAAFP;

Christopher Riley , MD;

Paul Newman , MD, MBA, MS;

Abstract: Although clinical pathways are most often developed for very narrow diagnoses with limited pharmaceutical treatments, they are even more needed to provide direction for symptom management involving multiple...

...

06/14/2017

Journal of Clinical Pathways

Research in Review

Underuse of Hospice Care for Blood Cancers Linked to Inadequate Services

06/14/2017

JCP Editors

Hematologic oncologists are hesitant to refer patients to hospice care due to their views of inadequate services offered there, according to study results published in Cancer (published online May 22, 2017;...

...

06/14/2017

Journal of Clinical Pathways

Research in Review

Aggressive Care Associated With Poorer Outcomes for Patients With NSCLC at End of Life

06/14/2017

JCP Editors

Aggressive care in the last month of life for patients with non–small cell lung cancer (NSCLC) is associated with lower family evaluations of end-of-life care. Patients with advanced NSCLC who are nearing...

...

06/14/2017

Journal of Clinical Pathways

Research in Review

Brain Metastases Resistant to Targeted Therapy Due to Gene Overexpression

06/14/2017

JCP Editors

A novel mechanism responsible for brain metastasis resistance to targeted therapy has been identified, which may help guide treatment strategies, according to a study published in Science Translational Medicine...

A...

06/14/2017

Journal of Clinical Pathways

Research in Review

PARP Inhibitors Crucial to the Future of Ovarian Cancer Treatment

06/12/2017

JCP Editors

The treatment landscape in the coming decade for ovarian cancers will likely feature poly ADP ribose polymerase (PARP) inhibitors in combination with other treatments, according to reports from a recent...

The...

06/12/2017

Journal of Clinical Pathways

Research in Review

Standard of Care Shift in ALK-Positive Lung Cancer

06/12/2017

JCP Editors

A second-generation inhibitor delays anaplastic lymphoma kinase (ALK)-positive lung cancer growth for a median of 15 months longer and causes fewer adverse events than the current standard of care, according to a new...

A...

06/12/2017

Journal of Clinical Pathways

Research in Review

Early PET Scan Improves Outcomes for Patients With Hodgkin Lymphoma

06/08/2017

JCP Editors

Response to positron emission tomography (PET) scan after two cycles of standard treatment allows for early treatment adaption for patients with early-stage Hodgkin lymphoma, according to research published in the...

...

06/08/2017

Journal of Clinical Pathways

Research in Review

Ovarian Cancer Associated With Out-of-Pocket Financial Burden

06/07/2017

JCP Editors

Patients receiving treatment for ovarian cancer experienced a significant out-of-pocket financial burden, due largely to cost disparities across treatment types and a lack of definitive treatment options, according...

...

06/07/2017

Journal of Clinical Pathways

Research in Review

Imaging Needed to Monitor Melanoma Brain Metastases During PD-1 Therapy

06/03/2017

JCP Editors

Central nervous system imaging is needed during programmed death 1 (PD-1) inhibitor therapy to monitor incidence, patterns of progression, and outcomes of melanoma brain metastases, according to research presented at...

...

06/03/2017

Journal of Clinical Pathways